Endevica Bio, a company developing peptide drug candidates with improved safety and efficacy properties, has closed a $10 million Series B funding round.
The company will use the proceeds from the financing for continuing the research and development of TCMBO7 for the treatment of cachexia, as well as for working capital or other general corporate purposes.
Cachexia is a life-threatening aspect to many diseases, including cancer.
Symptoms include lack of appetite and a loss of muscle disproportionate to the reduction in caloric intake.
Russell Potterfield, CEO and Executive Chairman of Endevica, said:
“We have never been more encouraged about the future of our company and the research it is doing to treat those suffering from cachexia.
“We look forward to the release of results from the Multiple Ascending Dose (MAD) arm of the Phase 1 study that was completed the end of December.”
Individuals suffering from cachexia often have a more difficult time doing day-to-day tasks, fatigue, a reduced quality of life and reduced survival.
In advanced cases, the condition can lead to multi-organ failure due to high metabolic rate-induced apoptosis.
According to the American Society of Clinical Oncology, cachexia is highly prevalent across malignancies and impacts approximately half of patients with advanced cancer.
“This funding will enable us to advance our research and development of TCMB07, which we believe has the potential to address a macro-scale patient population with cachexia, a condition that worsens health outcomes of patients with many chronic illnesses, not only cancer.
“As we add to our scientific team over the next few months, we look forward to advancing the clinical development of TCMB07, achieving additional milestones, and helping the millions of people suffering with cachexia.”
Healthcare innovators and leaders honoured at Imprivata HealthCon user group and awards ceremony
Wearable communication system may reduce digital health divide
Molecule trains the immune system to prevent cancer
Diabetes patients urged to use fitness games with caution
Urgent work needed to tackle ‘substantial’ digital health inequality
eSight: “The technology has the potential to change someone’s life”
Microsoft invests £2.5 billion in UK AI
TMS shows promise in tackling depression ‘epidemic’
AI depression app set for NHS clinical trial
UK Biobank releases world’s largest single set of sequencing data
- Diagnostics4 weeks ago
3D model will advance understanding of spinal injury pathology
- Opinion1 week ago
Why it’s time to revisit workplace mental health initiatives and make them work for everyone
- AI3 weeks ago
AI can help predict survival outcomes for cancer patients
- Research5 days ago
Tackling the diagnostic testing sustainability problem